• Jun. 2, 2015, 12:30 PM
    • According to Bloomberg, AstraZeneca (AZN +0.1%) CEO Pascal Soriot said that his firm would consider buying a company like Juno Therapeutics (JUNO +12.9%).
    • This isn't too surprising since oncology represents only 11% of AZN's business. CAR-Ts are all the rage in the cancer space. If their initial success can be validated in late-stage trials, they will command premium prices once approved, probably in the neighborhood of $500K per procedure. Acquiring one of the leaders would be a logical move for most members of Big Pharma or a number of larger biotechs. Juno's market cap is only $5.5B so it is not expensive if viewed on a long term basis.
    • Related tickers: (KITE +5.4%)(BLUE -0.5%)(BLCM +8.2%)(ZIOP +4%)(CLLS +4.4%)
    | Jun. 2, 2015, 12:30 PM | 15 Comments
Company Description
ZIOPHARM Oncology, Inc. is a biopharmaceutical company currently in developmental stage that seeks to acquire, develop and commercialize, on its own or with commercial partners, a diverse portfolio of cancer therapies. The company also has a portfolio of small molecule drug candidates, which are... More
Sector: Healthcare
Industry: Biotechnology
Country: United States